<img alt="" src="https://secure.perk0mean.com/171547.png" style="display:none;">
CALL US +44 (0)1462 440 084 | +1 919-882-2016 | Contact | Submit RFI

[Free Whitepaper]

Designing and Analyzing
Hemophilia Clinical Trials

Hemophilia is a condition which affects the blood’s ability to clot, thus causing a person to bleed (both internally and externally) more frequently and for longer, have painful localized swellings, cause deformities in joints, have a strikingly reduced quality of life and ultimately reduced life expectancy. There are several types of hemophilia, the most common of which are hemophilia A (effecting ~ 1 in 5,000 males) and hemophilia B (effecting ~ 1 in 30,000 males).

 

This whitepaper focuses on considerations for designing and analyzing clinical trials for treatment of Hemophilia A.

Key areas explored within this White Paper include:

  • An Introduction to Hemophilia
  • Current treatments for Hemophilia
  • Challenges involved with studying Hemophilia Clinical Trials 
    • Large amount of information for statistically meaningful results
    • Competition for patients in trials
    • Inhibitors Development
    • Factors that result in lengthy and ethically questionable design  
    • Quantifying endpoints
    • Pharmacokinetics
  • Good Practices
    • Recruitment
    • Safety Information
    • Selecting the correct patients

 

Please fill out the form on the right to immediately receive your free copy of this paper.

Download this paper